Xia, Li published the artcileROR¦Ãt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers, Category: catalysis-chemistry, the publication is Journal of Experimental & Clinical Cancer Research (2022), 41(1), 155, database is CAplus and MEDLINE.
The overall response rate to checkpoint blockade remains unsatisfactory, partially due to the immune-suppressive tumor microenvironment. A retinoic acid-related orphan receptor ¦Ãt (ROR¦Ãt) agonist (LYC-55716) is currently used in clin. trials combined with anti-PD-1, but how the Th17 cell transcription factor ROR¦Ãt enhances antitumor immunity of PD-1 in the tumor microenvironment remains elusive. The expression of mRNA was analyzed using qPCR assays. Flow cytometry was used to sort and profile cells. Cell migration was analyzed using Transwell assays. Biacore was used to determine the binding affinity to the ROR¦Ãt protein. The ROR¦Ãt GAL4 cell-based reporter gene assay was used to measure activity in the ROR¦Ãt driven luciferase reporter gene expression. We designed a potent and selective small-mol. ROR¦Ãt agonist (8-074) that shows robust antitumor efficacy in syngeneic tumor models and improves the efficacy of anti-PD-1 in a murine lung cancer model. ROR¦Ãt agonist treatment increased intratumoral CD8+ T cells, which were correlated with CXCL10 and monocyte-derived dendritic cells (MoDCs). In addition, the ROR¦Ãt agonist promoted Type 17 T cell migration by upregulating CCL20 and CCR6 expression, and Type 17 T cell tumor infiltration. CCL20 induces MoDCs migration, and CXCL10 derived from MoDCs promotes CD8+ T cell migration. Our results revealed that the ROR¦Ãt agonist improved the efficacy of anti-PD-1. The ROR¦Ãt agonist increased the migration of MoDCs, which increased the local levels of CXCL10, thus promoting CD8+ T cell tumor infiltration. Our findings provide the mechanistic insights implicating the ROR¦Ãt agonist in immunotherapy and offer a strategy for targeting the ROR¦Ãt agonist to improve PD-1 antibody efficacy in cancers.
Journal of Experimental & Clinical Cancer Research published new progress about 2055536-64-4. 2055536-64-4 belongs to catalysis-chemistry, auxiliary class Metabolic Enzyme,ROR, name is (S)-3-(6-(3-(Difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)-2,2-dimethylpropanoic acid, and the molecular formula is C20H18BrN3, Category: catalysis-chemistry.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia